Literature DB >> 4042542

Serum immunoreactive erythropoietin in hypoxic lung disease with and without polycythaemia.

J A Wedzicha, P M Cotes, D W Empey, A C Newland, J P Royston, R C Tam.   

Abstract

We studied 20 patients with chronic airflow obstruction, 10 patients without polycythaemia and 10 patients with compensatory polycythaemia having respectively mean red cell mass 24.7 (SD 4.2) and 47.8 (SD 7.5) ml/kg, mean daytime PaO2 7.6 and 6.9 kPa, mean FEV1 0.85 and 0.821. Groups were matched for severity of daytime arterial hypoxaemia but nocturnal arterial oxygen desaturation was more severe in the patients with polycythaemia than in those without. We also studied six additional patients with chronic airflow obstruction and polycythaemia and 19 normal controls. Estimates of serum immunoreactive erythropoietin (siEp) in those without polycythaemia were 19 m-i.u./ml (geometric mean) with 95% confidence range 11-35 m-i.u./ml and stable during 3 months. In those with polycythaemia they were similar and consistent in five and, in the other five, higher on at least one occasion. There was no significant difference between siEp in daytime (12.00 hours to 16.00 hours) and morning (07.00 hours) samples but geometric mean estimates of erythropoietin in paired daytime and morning samples were higher and more variable in patients with polycythaemia than in those without. The geometric mean estimate of siEp in all patients with chronic airflow obstruction and polycythaemia was greater than in normal subjects but, despite secondary polycythaemia, siEp could be in the range for normal subjects. In the patients with polycythaemia we were unable to predict the finding of normal or elevated siEp. Changes in siEp after erythrapheresis (10-26% reduction in packed cell volume) were observed in the 10 patients with polycythaemia and in one without. One month after erythrapheresis, packed cell volume remained below and siEp was above initial pretreatment levels, implying an erythropoietin secretory response and that the development of secondary polycythaemia had induced a fall in siEp.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042542     DOI: 10.1042/cs0690413

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  British Thoracic Society summer meeting. 11-13 July 1990, Birmingham. Abstracts.

Authors: 
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

2.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

3.  Intermittent hypoxia in patients with unexplained polycythaemia.

Authors:  J C Moore-Gillon; D F Treacher; E J Gaminara; T C Pearson; I R Cameron
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

4.  Proceedings of the British Thoracic Society. 12-14 July 1989, University of Southampton. Abstracts.

Authors: 
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

5.  Does obstructive sleep apnea increase hematocrit?

Authors:  Jong Bae Choi; José S Loredo; Daniel Norman; Paul J Mills; Sonia Ancoli-Israel; Michael G Ziegler; Joel E Dimsdale
Journal:  Sleep Breath       Date:  2006-09       Impact factor: 2.816

6.  Anemia of aging and obstructive sleep apnea.

Authors:  Amir M Khan; Santoro Ashizawa; Violetta Hlebowicz; David W Appel
Journal:  Sleep Breath       Date:  2010-02-17       Impact factor: 2.816

7.  Erythropoietin concentrations in obstructive sleep apnoea.

Authors:  J M Goldman; R M Ireland; M Berthon-Jones; R R Grunstein; C E Sullivan; J C Biggs
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

Review 8.  The human side of hypoxia-inducible factor.

Authors:  Thomas G Smith; Peter A Robbins; Peter J Ratcliffe
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.